Theravance Biopharma
TBPH
94 hedge funds and large institutions have $1.84B invested in Theravance Biopharma in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 37 increasing their positions, 26 reducing their positions, and 8 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 26
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
12% more capital invested
Capital invested by funds: $1.65B → $1.84B (+$191M)
2% more funds holding
Funds holding: 92 → 94 (+2)
1.41% more ownership
Funds ownership: 85.37% → 86.78% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
47% less call options, than puts
Call options by funds: $1.06M | Put options by funds: $1.99M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$38.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$36.8M |
| 3 |
BNP Paribas Asset Management
Paris,
France
|
+$6.26M |
| 4 |
BlackRock
New York
|
+$4.86M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$18.3M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$14.2M |
| 3 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$6.97M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.34M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.13M |
TBPH Hedge Fund Activity: Q2 2017 in Review
94 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2017, worth a combined $1.84B — up 12% from $1.65B a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new TBPH positions and 8 closed out — a net gain of 3 holders — while 37 added to existing stakes and 26 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $38.5M. The largest seller was Cormorant Asset Management, cutting an estimated $18.3M.
- 94 institutional investors held Theravance Biopharma (TBPH) as of Q2 2017, up from 92 in Q1 2017.
- Funds reported $1.84B of Theravance Biopharma stock for Q2 2017, up 12% quarter-over-quarter.
- 11 funds opened new Theravance Biopharma positions in Q2 2017 and 8 closed out, a net change of +3 holders.
- The largest Theravance Biopharma buyer in Q2 2017 was Fidelity Investments, an estimated $38.5M added.
- The largest Theravance Biopharma seller in Q2 2017 was Cormorant Asset Management, an estimated $18.3M sold.
Based on aggregated 13F filings for Q2 2017.